Worldwide Musculoskeletal Partnering Deals Directory, 2014-2020

News provided by

Jul 10, 2020, 12:00 ET

DUBLIN, July 10, 2020 /PRNewswire/ -- The "Global Musculoskeletal Partnering 2014-2020: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

This report provides the full collection of Musculoskeletal disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.

Trends in Musculoskeletal dealmaking in the biopharma industry since 2014
Analysis of Musculoskeletal deal structure
Access to headline, upfront, milestone and royalty data
Access to hundreds of Musculoskeletal deal contract documents
Comprehensive access to over 450 Musculoskeletal deal records
The leading Musculoskeletal deals by value since 2014
Most active Musculoskeletal dealmakers since 2014

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Musculoskeletal disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Musculoskeletal deals.

The report presents financial deal terms values for Musculoskeletal deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Musculoskeletal dealmaking trends.

Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Musculoskeletal dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Musculoskeletal deals since 2014. Deals are listed by headline value. The - Chapter includes the top 25 most active Musculoskeletal dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to Musculoskeletal deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all Musculoskeletal partnering deals by specific Musculoskeletal target announced since 2014. The - Chapter is organized by specific Musculoskeletal therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Musculoskeletal partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Musculoskeletal partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Musculoskeletal technologies and products.

Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are the sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Companies Mentioned

3SBio
A2A Pharmaceuticals
Abbvie
AbCellera
Abiogen Pharma
Ablynx
Actigraph
Activbody
Adaptive Health
Adcock Ingram
Advanced BioMatrix
AEONSurgical
AGC Asahi Glass
Akashi Therapeutics
AKL Research and Development
AlfaMed
AliMed
Alize Pharma
Allergan
AlloSource
All Star Health Brands
Almirall
Alpine Immune Sciences
Alvotech
Alzheimer's Association
Amedica
Amend Surgical
American Association of Neuromuscular & Electrodiagnostic Medicine
American Diabetes Association
Amgen
AmorChem
AMRA
Anagenesis Biotechnologies
Analysis Group
Andrus
Anika Therapeutics
ANI Pharmaceuticals
Antibe Therapeutics
Apexigen
Apple
Apsen Farmacutica
Aralez Pharmaceuticals
Aratana Therapeutics
Army & Air Force Exchange Service
Arthrex
Artialis
Ascendis Pharma
AskAt
Asklepios Biopharmaceutical
Aspen Holding
Astellas Pharma
AstraZeneca
Athrotech
Atlangram
Audentes Therapeutics
Australian Research Council
Avalere Health
AveXis
Avion Pharmaceuticals
Axiom Worldwide
Axovant Sciences
Axxess Pharma
Azellon Cell Therapeutics
Aziyo Biologics
Back-A-Line
Bacterin International
Baebies
Bauerfeind
Baxter International
Benitec Biopharma
BGI
Biametrics
Bill and Melinda Gates Foundation
Biogen
BioMarin Pharmaceutical
Biomedical Catalyst Fund (UK)
BioMed X Innovation Center
BionX Medical Technologies
BioPharma Forest
Bioventus
BioVinc
Blue Belt Technologies
Boehringer Ingelheim
Bone Biologics
BoneSupport
Bone Therapeutics
Boston Dynamics
Brigham and Women's Hospital
Bristol-Myers Squibb
BSN Medical
Cadila Pharmaceuticals
Calchan Holdings
California Institute for Biomedical Research
California Institute for Regenerative Medicine
Calimmune
Camargo Pharmaceutical Services
Camber Spine Technologies
Can-Fite BioPharma
Capricor Therapeutics
CareFirst BlueCross BlueShield
Carestream Health
Carlina Technologies
Carpal Aid
Casper Pharma
Catabasis Pharmaceuticals
Cedars-Sinai Medical Center
Celgene
Cellthera Pharma
Cell Therapy Catapult
Celltrion
Cellular Biomedicine
Cel Sci
Centinel Spine
Centogene
Centre National de la Recherche Scientifique
Changshan Pharm
CheckPoint Immunology
Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Children's Hospital Boston
Children's Hospital of Philadelphia
Children's Research Institute
Cipher Pharmaceuticals
Cipla
Cloud Pharmaceuticals
CMS Medical
Coapt
Cocoon Biotech
Coeptis Pharmaceuticals
Coherus Biosciences
Collaborative Trajectory Analysis Project
Collagen Solutions PLC
and many, many more!

For more information about this report visit https://www.researchandmarkets.com/r/fzsrfy

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets